Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer

Conclusion: The reported findings support the use of iodine-based and 68Ga-labeled variants as a convenient strategy for developing astatinated compounds and confirm [211At]PSAt-3 as a promising radiopharmaceutical for targeted α-therapy.

Source: Journal of Nuclear Medicine - April 1, 2024 Category: Nuclear Medicine Authors: El Fakiri, M., Ayada, N., Muller, M., Hvass, L., Gamzov, T. H., Clausen, A. S., Geis, N. M., Steinacker, N., Hansson, E., Lindegren, S., Aneheim, E., Jensen, H., Eder, A.-C., Jensen, A. I., Poulie, C. B. M., Kjaer, A., Eder, M., Herth, M. M. Tags: Basic Science Investigations Source Type: research